Recombinant Anti-Human CD38 VHH Single Domain Antibody (CAT#: NABL-079)

Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100. https://doi.org/10.1016/j.cmet.2017.10.006

The research investigates the role of the CD38-NAD+ axis in regulating anti-tumor T cell responses in immunotherapy. The study demonstrates that hybrid Th1/17 cells, which combine the effector properties of Th1 cells with the stemness features of Th17 cells, exhibit superior tumor control capabilities. These hybrid cells show enhanced intracellular NAD+ levels, which activate the histone deacetylase Sirt1, leading to deacetylation and activation of the transcription factor Foxo1. This NAD+-Sirt1-Foxo1 pathway is crucial for maintaining both the effector function and long-term persistence of T cells. Importantly, the expression of CD38, which functions as a NADase, inversely correlates with NAD+ levels and regulates the anti-tumor potential of T cells. The researchers found that genetic ablation or antibody-mediated targeting of CD38 on T cells increased NAD+ levels and improved tumor control.
Creative Biolabs provided an anti-CD38 VHH Single Domain Antibody (CAT#: NABL-079) that played a significant role in this research. This antibody was used to block CD38 expression on T cells, which helped demonstrate that antibody-mediated targeting of CD38 could enhance T cell-mediated tumor control. By inhibiting CD38 with this antibody, the researchers showed that it's possible to metabolically reprogram T cells to maintain higher NAD+ levels, leading to improved oxidative phosphorylation, enhanced glutaminolysis, and altered mitochondrial dynamics, all of which contributed to superior tumor control even when using non-specialized Th0 anti-tumor T cells.

Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100. https://doi.org/10.1016/j.cmet.2017.10.006

This study investigates the role of CD38-mediated NAD+ metabolism in the anti-tumor function of T cells. The researchers explored how CD38 expression influences the metabolic pathways of T cells within the tumor microenvironment, specifically focusing on its impact on mitochondrial biogenesis and function. By analyzing CD38-deficient and wild-type T cells, the study demonstrated that CD38 plays a crucial role in regulating NAD+ levels, which in turn affects the T cells' metabolic fitness and anti-tumor capabilities. The findings suggest that targeting CD38 could enhance the efficacy of T cell-based immunotherapies by improving T cell metabolism and function within tumors.
Creative Biolabs provided critical reagents for this study, including the Anti CD38 VHH Single Domain Antibody (Cat# NABL-079). This antibody was essential for the experiments involving CD38 detection and functional analysis in T cells. By enabling precise measurement and modulation of CD38 activity, the antibody facilitated a deeper understanding of how CD38 regulates T cell metabolism and its potential as a therapeutic target. The contribution of Creative Biolabs' products significantly advanced the study's investigation into enhancing T cell-mediated anti-tumor responses through metabolic modulation.